Whats happening to the biosimilars division????

Discussion in 'Pfizer' started by anonymous, May 13, 2019 at 9:50 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Now that the worthless BAM's are going into clinics and the Xeljanz reps can talk price is the division doomed???
     

  2. anonymous

    anonymous Guest

    Should be put out if it’s misery. Doomed from the start. Poooooor “ management”, the usual from Pfizer......
     
  3. anonymous

    anonymous Guest

    Trolls
     
  4. anonymous

    anonymous Guest

    Yep, that’s their management.
     
  5. anonymous

    anonymous Guest

    They may be trolls but they have a point. Biosimilars is gone from Pfizer. Mylan just paid Biocon $5 million to postpone a decision on whether to take their biosimilar insulin glargine. Why! It it was so attractive why postpone a decision? Because Pfizer wants to get rid of it. Look at Merck... they told Samsung Bioepis they don’t want their biosimilar glargine, that whole insulin segment is just too much under price pressure.
     
  6. anonymous

    anonymous Guest

    Lets have another reorg!! The last one was a lot of fun!!!
     
  7. anonymous

    anonymous Guest

    Biosimilars is an interesting topic., in the Hem division, they will be selling a Biosimilar along with the 4 products they already sell (total of 5)
     
  8. anonymous

    anonymous Guest

     
  9. anonymous

    anonymous Guest

    POOR Launch Plan
    Poor Leadership
    Reps are weakest ones in all of Pfe!
    Pfe is trying to sell a "generic" at same Branded Prices, so 3yrs later still less than 5% share.
    They need to cut price by 50% like traditional generic pricing models, or sell off the division.
    If Teva would have launched generic Lipitor at same branded price, Lipitor would not have lost any share or sales!
     
  10. anonymous

    anonymous Guest

    Simple result of greed. Government gave us every break to get biosimilars off the ground yet Pfizer sold as just another branded product with typical big Pharma sales model. And then priced actually at the same or slightly lower than reference product.
     
  11. anonymous

    anonymous Guest

    No, John Young ego and arrogance, plus spineless marketer's like Lynch, Spotz, & Schwartz sealed biosims fate.
     
  12. anonymous

    anonymous Guest

    Pfizer could screw up a one car funeral.
    Too much incompetence in management, especially at the top.
     
  13. anonymous

    anonymous Guest

    The incompetency and idiocy within Pfizer is now staggering! This can never be a growth company given all the rolled up fake numbers being thrown together for forecasts without a shred of credible evidence. Forget "fake news" by the media, now we have "fake financials" driven by leadership.
     
  14. anonymous

    anonymous Guest

    Where Joe T??? Such a great guy.. did he leave the company??
     
  15. anonymous

    anonymous Guest

    If he has any brains he has.
     
  16. anonymous

    anonymous Guest

    B. St. Jon is a old cranky jerk
     
  17. anonymous

    anonymous Guest

    Maybe we should call Coherus to see how it’s done right
     
  18. anonymous

    anonymous Guest

    The whole Biosimilars went south late in 2018. It’s a race to the bottom with price. You have to be the first or second to market, after that it’s a s...show.
    Poor, floundering leadership.
     
  19. anonymous

    anonymous Guest

    Bingo!
     
  20. anonymous

    anonymous Guest

    Get rid of the idiots...D. K. in the northeast..LOSER